Trial Profile
An exploratory analysis of the role of dasatinib in preventing progression of disease in bone in patients with metastatic breast cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Apr 2014
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Paclitaxel
- Indications Bone metastases; Breast cancer
- Focus Therapeutic Use
- 23 Apr 2014 New trial record